<?xml version='1.0' encoding='utf-8'?>
<document id="29297772"><sentence text="Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase."><entity charOffset="121-130" id="DDI-PubMed.29297772.s1.e0" text="rapamycin" /></sentence><sentence text="1" /><sentence text=" CC-223 was studied in vitro for metabolism and drug-drug interactions (DDI), and in clinic for interaction with ketoconazole"><entity charOffset="113-125" id="DDI-PubMed.29297772.s3.e0" text="ketoconazole" /></sentence><sentence text=" 2" /><sentence text=" In vitro, human metabolites of CC-223 included O-desmethyl CC-223 (M1), keto (M2), N-oxide (M3) and imine (M13), with M1 being the most prominent metabolite"><entity charOffset="48-66" id="DDI-PubMed.29297772.s5.e0" text="O-desmethyl CC-223" /><entity charOffset="73-77" id="DDI-PubMed.29297772.s5.e1" text="keto" /><entity charOffset="84-91" id="DDI-PubMed.29297772.s5.e2" text="N-oxide" /><entity charOffset="101-106" id="DDI-PubMed.29297772.s5.e3" text="imine" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e0" e2="DDI-PubMed.29297772.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e0" e2="DDI-PubMed.29297772.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e0" e2="DDI-PubMed.29297772.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e0" e2="DDI-PubMed.29297772.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e1" e2="DDI-PubMed.29297772.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e1" e2="DDI-PubMed.29297772.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e1" e2="DDI-PubMed.29297772.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e2" e2="DDI-PubMed.29297772.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29297772.s5.e2" e2="DDI-PubMed.29297772.s5.e3" /></sentence><sentence text=" 3" /><sentence text=" CC-223 was metabolized by CYP2C9 and CYP3A, while metabolism of M1 was mediated by CYP2C8 and CYP3A" /><sentence text=" Ketoconazole increased CC-223 and M1 exposure by 60-70% in healthy volunteers"><entity charOffset="1-13" id="DDI-PubMed.29297772.s8.e0" text="Ketoconazole" /></sentence><sentence text=" 4" /><sentence text=" CC-223 (IC50 ≥ 27 µM) and M1 (IC50 ≥ 46 µM) were inhibitors of CYP2C9 and CYP2C19 in human liver microsomes" /><sentence text=" CC-223 and M1 were moderate inducers of CYP3A in human hepatocytes" /><sentence text=" 5" /><sentence text=" CC-223 was a substrate of BCRP, and M1 was a substrate of P-gp and BCRP" /><sentence text=" CC-223 was an inhibitor of P-gp (IC50 = 3" /><sentence text="67 µM) and BCRP (IC50 = 11" /><sentence text="7 µM), but at a clinically relevant concentration showed no inhibition of other transporters examined" /><sentence text=" M1 is a weak inhibitor of P-gp and BCRP" /><sentence text=" 6" /><sentence text=" PBPK model of CC-223 and M1 was developed and verified using clinical results" /><sentence text=" Model based predictions of DDI with ketoconazole were in agreement with observed results enabling prospective predictions of DDIs between CC-223 and CYP3A4 inhibitors"><entity charOffset="37-49" id="DDI-PubMed.29297772.s20.e0" text="ketoconazole" /></sentence><sentence text="" /></document>